Compare · ABBV vs ELAN
ABBV vs ELAN
Side-by-side comparison of AbbVie Inc. (ABBV) and Elanco Animal Health Incorporated (ELAN): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ABBV and ELAN operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- ABBV is the larger of the two at $469.68B, about 37.5x ELAN ($12.54B).
- ABBV has been more active in the news (17 items in the past 4 weeks vs 14 for ELAN).
- ABBV has more recent analyst coverage (25 ratings vs 24 for ELAN).
- Company
- AbbVie Inc.
- Elanco Animal Health Incorporated
- Price
- -
- -
- Market cap
- $469.68B
- $12.54B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NYSE
- NYSE
- IPO
- 2012
- 2018
- News (4w)
- 17
- 14
- Recent ratings
- 25
- 24
AbbVie Inc.
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; AndroGel for males diagnosed with symptomatic low testosterone; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production. The company was incorporated in 2012 and is based in North Chicago, Illinois.
Elanco Animal Health Incorporated
Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as functional nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands. The company sells its products to third-party distributors; veterinarians; and farm animal producers, including beef and dairy farmers, as well as pork, poultry, and aquaculture operations in approximately 90 countries in North America, Europe, the Middle East, Africa, Latin America, and the Asia-Pacific. Elanco Animal Health Incorporated was founded in 1954 and is headquartered in Greenfield, Indiana.
Latest ABBV
- AbbVie to Present New Data at WCLC 2026 Showcasing Innovation Across Lung Cancer Pipeline
- EVP, CHIEF BUS/STRAT OFFICER Donoghoe Nicholas sold $8,177,500 worth of shares (32,710 units at $250.00) and exercised 32,710 shares at a strike of $79.02 (SEC Form 4)
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- A New Category Is Forming in Medical Aesthetics. Independent Research Has Started Sizing It.
- AbbVie Announces 2026 AbbVie Immunology Scholarship Recipients, Celebrating 10 Years of Support
- AbbVie upgraded by Wolfe Research with a new price target
- The GLP-1 Boom Created a Tissue Gap Fillers Were Not Built For
- Allergan Aesthetics Refreshes Allergan Partner Privileges® to Better Support Today's Modern Aesthetics Practices
- SEC Form 424B5 filed by AbbVie Inc.
- AbbVie Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
Latest ELAN
- SEC Form 4 filed by Officer Modi Rajeev A.
- SEC Form 4 filed by EVP and CFO Vanhimbergen Robert M
- SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N
- Director Kurzius Lawrence Erik bought $935,920 worth of shares (40,000 units at $23.40), increasing direct ownership by 27% to 188,647 units (SEC Form 4)
- GC AND CORP SEC O'Neill Shiv bought $94,273 worth of shares (3,998 units at $23.58), increasing direct ownership by 5% to 87,832 units (SEC Form 4)
- Director Harrington Michael J bought $109,100 worth of shares (5,000 units at $21.82), increasing direct ownership by 4% to 131,451 units (SEC Form 4)
- SEC Form 4 filed by PRESIDENT, CEO AND DIRECTOR Simmons Jeffrey N
- EVP and CFO Vanhimbergen Robert M bought $96,926 worth of shares (4,200 units at $23.08), increasing direct ownership by 3% to 137,516 units (SEC Form 4)
- SEC Form 4 filed by Officer Modi Rajeev A.
- Director Herendeen Paul bought $236,850 worth of shares (10,000 units at $23.68), increasing direct ownership by 10% to 111,687 units (SEC Form 4)